老年原发性中枢神经系统淋巴瘤患者:美国20家癌症中心的生存与预后分析
回顾性分析美国20家学术中心539例新诊断且年龄≥60岁的原发性中枢神经系统淋巴瘤患者,中位年龄70岁。中位随访58个月,中位无进展生存期17个月,中位总生存期43个月;含高剂量甲氨蝶呤联合方案诱导及维持治疗者结局较好,多种老年评估指标与不良预后相关。
要点
- 539例≥60岁患者中位年龄70岁,46%存在至少一种老年综合征,36%日常生活活动能力受损。
- 中位无进展生存期17个月(95%CI 13-22),中位总生存期43个月(95%CI 31-56)。
- MTR方案3年无进展生存率55%、总生存率74%;接受维持治疗者3年无进展生存率65% vs 未接受者45%(P=0.02)。
核心结论
- 老年原发性中枢神经系统淋巴瘤患者采用含高剂量甲氨蝶呤联合方案诱导及维持治疗时结局似更优,多种预后因素包括老年评估指标与较差结局相关。
研究设计与样本
- 回顾性分析美国20家学术中心539例新诊断的原发性中枢神经系统淋巴瘤患者,年龄≥60岁。
主要发现
- 中位年龄70岁(范围60-88);46%存在至少一种老年综合征;中位CIRS-G评分为6分(范围0-27);36%存在日常生活活动能力受损。
- 70%患者达到缓解,14%接受巩固性自体造血干细胞移植,24%接受维持治疗。
- 中位随访58个月,中位无进展生存期17个月(95%CI 13-22个月),中位总生存期43个月(95%CI 31-56个月)。
- MTR方案3年无进展生存率55%、总生存率74%;单药甲氨蝶呤±利妥昔单抗3年无进展生存率30%(P=0.0002)、总生存率47%(P=0.0072)。
- 接受维持治疗者3年无进展生存率65% vs 未接受者45%(P=0.02),3年总生存率84% vs 61%(P=0.0003)。
关键数值与推荐
- 多因素分析中,诊断时年龄增加和ECOG体能状态较差与较差的无进展生存期相关;年龄、低白蛋白血症、较高CIRS-G评分和ECOG体能状态对总生存期有不良影响。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There is a paucity of large-scale data delineating outcomes and prognostication of older patients with primary central nervous system lymphoma (PCNSL). We retrospectively analyzed 539 newly-diagnosed PCNSL patients ages ≥60 years across 20 U.S. academic centers. The median age was 70 years (range 60-88); at least one geriatric syndrome was present in 46%; the median Cumulative Index Ratings Scale-Geriatrics (CIRS-G) score was 6 (range, 0-27); and 36% had impairment in activities of daily living (ADL). The most common induction regimens were high-dose methotrexate (HD-MTX) ± rituximab; methotrexate, temozolomide, rituximab (MTR); and rituximab, methotrexate, procarbazine, vincristine (R-MPV). Overall, 70% of patients achieved remission, with 14% undergoing consolidative autologous stem cell transplant (ASCT) and 24% receiving maintenance. With 58-month median follow-up, median progression-free survival (PFS) and overall survival (OS) were 17 months (95% CI 13-22 months) and 43 months (95% CI 31-56 months), respectively. Three-year PFS and OS were highest with MTR (55% and 74%, respectively). With single-agent methotrexate ± rituximab, 3-year PFS and OS were 30% (p = .0002) and 47% (p = .0072). On multivariate analysis, increasing age at diagnosis and Cooperative Oncology Group (ECOG) performance status (PS) was associated with inferior PFS; age, hypoalbuminemia, higher CIRS-G score, and ECOG PS adversely affected OS. Among patients receiving maintenance, 3-year PFS was 65% versus 45% without maintenance (p = 0.02), with 3-year OS of 84% versus 61%, respectively (p = .0003). Altogether, outcomes in older PCNSL patients appeared optimized with HD-MTX combination induction regimens and maintenance therapy. Furthermore, several prognostic factors, including geriatric measures, were associated with inferior outcomes.
引用
- David KA, Sundaram S, Kim SH, et al. Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers. Am J Hematol. 2023. PMID: 36965007. doi:10.1002/ajh.26919
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。